Advanced search

Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria

(2005) KIDNEY INTERNATIONAL. 67(suppl. 93).
Author
Organization
Abstract
Objectives. The purpose of this study was to project the cumulative incidence of end-stage renal disease (ESRD), life expectancy, and costs in a Spanish setting of treating patients with diabetes, hypertension, and microalbuminuria with either standard hypertension treatment alone or standard hypertension treatment plus irbesartan 300 mg daily. Methods. A peer-reviewed, published Markov model that simulated progression from microalbuminuria to nephropathy, doubling of serum creatinine, ESRD, and all-cause mortality in patients with hypertension, type 2 diabetes, and microalbuminuria was adapted to a Spanish setting. Two strategies were compared: (1) irbesartan versus (2) standard hypertension care with comparable blood pressure control; both began in diabetic hypertensive subjects with microalbuminuria. Cumulative incidence of ESRD, costs, and life expectancy were projected for a hypothetical cohort of 1000 subjects. Future costs and life expectancy were discounted at 3% yearly. A 25-year time horizon and third party payer perspective were used. Results. When compared to standard blood pressure control, irbesartan was projected to reduce the cumulative incidence of ESRD from (mean +/- standard deviation) 24 +/- 1% to 9 +/- 2%, save 11,082 +/- 2,996, and add 1.40 +/- 0.27 life years per treated patient. The superiority of irbesartan over standard care was robust under a wide range of plausible assumptions. Conclusion. Treating patients with hypertension, microalbuminuria, and type 2 diabetes with irbesartan was projected to reduce the incidence of ESRD, extend life, and reduce costs.
Keywords
irbesartan, costs, cost-effectiveness, microalbuminuria, nephropathy, modeling, end-stage renal disease, Spain, RENAL-DISEASE, NEPHROPATHY, MELLITUS

Citation

Please use this url to cite or link to this publication:

Chicago
Palmer, AJ, Lieven Annemans, S Roze, P Lapuerta, R Chen, S Gabriel, P Carita, et al. 2005. “Irbesartan Is Projected to Be Cost and Life Saving in a Spanish Setting for Treatment of Patients with Type 2 Diabetes, Hypertension, and Microalbuminuria.” Kidney International 67 (suppl. 93): 52.
APA
Palmer, AJ, Annemans, L., Roze, S., Lapuerta, P., Chen, R., Gabriel, S., Carita, P., et al. (2005). Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. KIDNEY INTERNATIONAL, 67(suppl. 93), 52.
Vancouver
1.
Palmer A, Annemans L, Roze S, Lapuerta P, Chen R, Gabriel S, et al. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. KIDNEY INTERNATIONAL. 2005;67(suppl. 93):52.
MLA
Palmer, AJ, Lieven Annemans, S Roze, et al. “Irbesartan Is Projected to Be Cost and Life Saving in a Spanish Setting for Treatment of Patients with Type 2 Diabetes, Hypertension, and Microalbuminuria.” KIDNEY INTERNATIONAL 67.suppl. 93 (2005): 52. Print.
@article{306018,
  abstract     = {Objectives. The purpose of this study was to project the cumulative incidence of end-stage renal disease (ESRD), life expectancy, and costs in a Spanish setting of treating patients with diabetes, hypertension, and microalbuminuria with either standard hypertension treatment alone or standard hypertension treatment plus irbesartan 300 mg daily. 
Methods. A peer-reviewed, published Markov model that simulated progression from microalbuminuria to nephropathy, doubling of serum creatinine, ESRD, and all-cause mortality in patients with hypertension, type 2 diabetes, and microalbuminuria was adapted to a Spanish setting. Two strategies were compared: (1) irbesartan versus (2) standard hypertension care with comparable blood pressure control; both began in diabetic hypertensive subjects with microalbuminuria. Cumulative incidence of ESRD, costs, and life expectancy were projected for a hypothetical cohort of 1000 subjects. Future costs and life expectancy were discounted at 3\% yearly. A 25-year time horizon and third party payer perspective were used. 
Results. When compared to standard blood pressure control, irbesartan was projected to reduce the cumulative incidence of ESRD from (mean +/- standard deviation) 24 +/- 1\% to 9 +/- 2\%, save 11,082 +/- 2,996, and add 1.40 +/- 0.27 life years per treated patient. The superiority of irbesartan over standard care was robust under a wide range of plausible assumptions. 
Conclusion. Treating patients with hypertension, microalbuminuria, and type 2 diabetes with irbesartan was projected to reduce the incidence of ESRD, extend life, and reduce costs.},
  author       = {Palmer, AJ and Annemans, Lieven and Roze, S and Lapuerta, P and Chen, R and Gabriel, S and Carita, P and Rodby, RA and De Zeeuw, D and Parving, HH and De Alvaro, F},
  issn         = {0085-2538},
  journal      = {KIDNEY INTERNATIONAL},
  keyword      = {irbesartan,costs,cost-effectiveness,microalbuminuria,nephropathy,modeling,end-stage renal disease,Spain,RENAL-DISEASE,NEPHROPATHY,MELLITUS},
  language     = {eng},
  number       = {suppl. 93},
  title        = {Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria},
  url          = {http://dx.doi.org/10.1111/j.1523-1755.2005.09312.x},
  volume       = {67},
  year         = {2005},
}

Altmetric
View in Altmetric
Web of Science
Times cited: